Ovarian cancer is one of the most commonly diagnosed cancers in women, accounting for more than 21,000 new cases each year (American Cancer Society). Ovarian cancer causes more deaths than any other cancer that occurs in the female reproductive system.
Rates of ovarian cancer have generally been falling, but recent revelations and lawsuits about the possible connection between talcum powder and ovarian cancer has renewed concerns about this common and often-deadly form of cancer.
Fortunately, many clinical trials are focused on new treatment methods or combinations of medications to treat ovarian cancer and extend and improve the lives of women who are dealing with this disease.
Let’s take a look at the 15 biggest trials focusing on ovarian cancer, including the number of locations where the trials are taking place, what the research is hoping to find and what stage the trial is in (phases range from Phase I to Phase IV — see more at the bottom of the page). All trials listed were registered with the National Cancer Institute in April 2020, and patients who are interested in particpating should consult with their doctors.
Letrozole With or Without Paclitaxel and Carboplatin
This trial studies letrozole (brand name Femara), a non-steroidal enzyme inhibitor, and how well it works with or without paclitaxel and carboplatin, which are both chemotherapy medications. Included in the study are stage II-IV low-grade cancers of the ovaries, as well as the fallopian tubes or peritoneum.
The drug lowers the amount of estrogen in the body, and researchers theorize that adding it to chemotherapy may work better in patients.
Locations: 423 sites in 43 states
Cediranib Maleate and Olaparib or Standard Chemotherapy
This trial aims to show how well cediranib maleate and olaparib, both inhibitor drugs, work when given together or separately in treating cancers of the ovaries, fallopian tubes of peritoneum. The trial also compares these drugs to standard chemotherapy.
These drugs may work to stop the growth of cancer cells by blocking necessary enzymes.
Locations: 337 sites in 49 states and Canada
New Drug (VB-111) With or Vs. Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer
This trial of a new drug, VB-111 (ofranergene obadenovec), aims to investigate the effects of the mediction on platinum-resistant ovarian cancer.
VB-111 is a first-in-class anticancer medication that uses a dual gene/viral mechanism to target tumors.
Locations: 27 sites in 20 states; expected to expand to 70 sites in U.S. and Israel
Addition of Tremelimumab to Olaparib for Recurrent Ovarian Cancer
Trial focuses on how well olaparib with or without tremelimumab works in treating patients with cancers of the ovaries, fallopian tubes of peritonium.
Olaparib is believed to stop the growth of tumor cells by blocking enzymes, and drugs like tremelimumab may help boost the body’s immune system, improving clinical outcomes.
Locations: 16 sites in 13 states
Comparison of TSR-042 and Niraparib Vs. Standard of Care Platinum-Based Therapy
This global trial studies newly diagnosed stage III or IV non-mucinous epithelial ovarian, fallopian tube or peritoneal cancer, comparing platinum-based therapy with TSR-042, a new anti-cancer drug, and niraparib vs. current standard of care platinum-based therapy alone.
Locations: 15 sites in 9 states
Carboplatin, Gemcitabine Hydrochloride and VX-970 for Recurrent and Metastatic Ovarian Cancer
This trial studies side effects and best dosages of gemcitabine hydrochloride and ATR kinase inhibitor VX-970, a new drug, and how well they work with carboplatin in treating patients with recurrent, metastatic ovarian cancer.
Researchers believe giving VX-970 with chemotherapy drugs may work better than chemotherapy alone.
Locations: 12 sites in 9 states
Combination of Niraparib and TSR-042 in Patients With Platinum-Resistant Ovarian Cancer
This trial focuses on a new drug, TSR-042, in combination with niraparib for patients with platinum-resistant ovarian cancer that’s advanced or relapsed.
Locations: 12 sites in 7 states
Onapristone in Patients with Progesterone Receptor-Positive Recurrent Ovarian Cancer
This trial is studying extended-release onapristone, an antiprotestogen, in treating patients with progesterone receptor-positive cancers of the ovaries, peritoneum or endometrium that has become recurrent.
Researchers theorize that hormone therapy with extended-release onapristone may stunt growth of gynecololgic cancer cells.
Locations: 7 sites in 2 states
Clinical Trial Phases
New disease treatments must go through several stages of research, called phases. They are:
- Phase I: Whether new treatment is safe and effective and what is the best way to administer it.
- Phase II: Whether one type of cancer responds to the new treatment.
- Phase III: Whether the new treatment is better than a previously standard treatment.
- FDA Approval: Between phases III and IV
- Phase IV: Find more information about long-term benefits and side effects.
While treatment options for cancers tend to vary depending on the location of the cancer, how advanced it is and other factors, the progress of scientific understanding is ongoing, with researchers constantly working to develop new treatments that can help save lives.
Used Talcum Baby Powder Have Cancer?
For those whose ovarian cancer was caused by exposure to asbestos, whether through the use of talcum powder or another means of exposure, compensation may be available, with or without the need to file a lawsuit. Complete the form or call us toll-free (800) 352-0871 to find out how to receive compensation.